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d Department of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USAThere were errors in Figs. 1 and 5 in the original publication of this
article. The corrected ﬁgures appear below.Fig. 1. Rad6B and β-catenin exhibit direct interactions. (A) Immu-
nohistochemical analysis of Rad6 (a, b, and c) and β-catenin (a’, b’,
and c’) in reduction mammoplasty (a, and a’) and clinical breast car-
cinomas (b, b’, c, and c’). (B) Immunoﬂuorescence localization of Rad6
(a, b and c) and β-catenin (a’, b’ and c’) in reduction mammoplasty0167-4889/$ – see front matter © 2012 Elsevier B.V. All rights reserved.
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48108, USA.(a–a”), inﬁltrating ductal carcinoma (b–b”), and WS-15 breast cancer
cells (c–c”). Magniﬁcation ×20 (a–a” and b–b”) and ×100 (c–c”). (C)
Co-immunoprecipitation analysis. Lane 1, 1/5th of MDA-MB-231
cytosol inputs. (D) Mapping β-catenin interacting regions. Pull-
down assays from GSH-beads with His-tagged wild type Rad6B
1–152 (lanes 9–11) and GST-tagged β-catenin 1–781 (lane 9),
β-catenin 131–422 (lane 10) or β-catenin 181–422 (lane 11) proteins.
Lanes 1–4, inputs of His-Rad6B, GST-β-catenin 1–781, GST-β-catenin
131–422, and GST-β-catenin 181–422, respectively. Lanes 5–8, control
GST, GST-β-catenin 1–781, GST-β-catenin 131–422, and GST-β-
catenin 181–422, respectively. Blots were probed with GST (upper)
and His (bottom) antibodies. (E) Mapping Rad6B interaction sites.
Pull-down assays were performed with His-tagged Rad6B 1–152
(lanes 4 and 7), Rad6B 50–152 (lanes 5 and 8) or Rad6B 116–152
(lanes 6 and 9) and GST-β-catenin 1–781 (lanes 4–9) on GSH-beads
(lanes 4–6) or Ni+2-beads (lanes 7–9). Lanes 1–3, inputs of Rad6B
1–152, Rad6B 50–152, Rad6B 116–152, and GST-β-catenin 1–781.
Blots were probed with His (upper) and GST (bottom) tag antibodies.
Rad6B/β-catenin interaction regions are shown schematically in the
right panels of D and E.
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tional activity. (A) TOP/Flash activities (mean±S.E.M.). * indicates
signiﬁcant difference as compared to control (Pb0.01). (B) TOP/
Flash activity assays with increasing amounts (1–4 μg) of wild type
or K394R-β-catenin. Lower panel, western blot analysis of indicated
proteins. (C) Rad6B mRNA expression relative to GAPDH (mean±
S.E.M.) in MCF-7 cells transfected with myc-tagged wild type ormutantβ-catenin vectors. * indicates signiﬁcant difference as compared
to control (Pb0.01). (D) Steady-state levels of the indicated proteins
in nontransfected (ﬁrst lane) or transfected with the indicated
β-catenin. (E) MG132 does not affect the steady state levels of
K394R-β-catenin. Myc tag antibody immunoblots of K394R- or wild
type (WT) β-catenin in MCF-7 cells with or without MG132
treatment.
